Literature DB >> 22171278

Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization.

Alexander W Tarr1, Richard A Urbanowicz, Dhanya Jayaraj, Richard J P Brown, Jane A McKeating, William L Irving, Jonathan K Ball.   

Abstract

Chronic hepatitis C virus (HCV) infection can persist even in the presence of a broadly neutralizing antibody response. Various mechanisms that underpin viral persistence have been proposed, and one of the most recently proposed mechanisms is the presence of interfering antibodies that negate neutralizing responses. Specifically, it has been proposed that antibodies targeting broadly neutralizing epitopes located within a region of E2 encompassing residues 412 to 423 can be inhibited by nonneutralizing antibodies binding to a less conserved region encompassing residues 434 to 446. To investigate this phenomenon, we characterized the neutralizing and inhibitory effects of human-derived affinity-purified immunoglobulin fractions and murine monoclonal antibodies and show that antibodies to both regions neutralize HCV pseudoparticle (HCVpp) and cell culture-infectious virus (HCVcc) infection albeit with different breadths and potencies. Epitope mapping revealed the presence of overlapping but distinct epitopes in both regions, which may explain the observed differences in neutralizing phenotypes. Crucially, we failed to demonstrate any inhibition between these two groups of antibodies, suggesting that interference by nonneutralizing antibodies, at least for the region encompassing residues 434 to 446, does not provide a mechanism for HCV persistence in chronically infected individuals.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22171278      PMCID: PMC3302288          DOI: 10.1128/JVI.06492-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine.

Authors:  B Dietzschold; M Gore; D Marchadier; H S Niu; H M Bunschoten; L Otvos; W H Wunner; H C Ertl; A D Osterhaus; H Koprowski
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

2.  Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection.

Authors:  Lin Liu; Brian E Fisher; Kimberly A Dowd; Jacquie Astemborski; Andrea L Cox; Stuart C Ray
Journal:  J Virol       Date:  2010-03-03       Impact factor: 5.103

3.  Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease.

Authors:  S Todo; A J Demetris; D Van Thiel; L Teperman; J J Fung; T E Starzl
Journal:  Hepatology       Date:  1991-04       Impact factor: 17.425

4.  Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.

Authors: 
Journal:  J Viral Hepat       Date:  1999-01       Impact factor: 3.728

5.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes.

Authors:  Nicasio Mancini; Roberta A Diotti; Mario Perotti; Giuseppe Sautto; Nicola Clementi; Giovanni Nitti; Arvind H Patel; Jonathan K Ball; Massimo Clementi; Roberto Burioni
Journal:  PLoS One       Date:  2009-12-11       Impact factor: 3.240

7.  Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation.

Authors:  Samira Fafi-Kremer; Isabel Fofana; Eric Soulier; Patric Carolla; Philip Meuleman; Geert Leroux-Roels; Arvind H Patel; François-Loïc Cosset; Patrick Pessaux; Michel Doffoël; Philippe Wolf; Françoise Stoll-Keller; Thomas F Baumert
Journal:  J Exp Med       Date:  2010-08-16       Impact factor: 14.307

Review 8.  Management of hepatitis C in liver transplant recipients.

Authors:  A Kuo; N A Terrault
Journal:  Am J Transplant       Date:  2006-03       Impact factor: 8.086

9.  Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo.

Authors:  Thomas von Hahn; Joo Chun Yoon; Harvey Alter; Charles M Rice; Barbara Rehermann; Peter Balfe; Jane A McKeating
Journal:  Gastroenterology       Date:  2006-12-03       Impact factor: 22.682

10.  Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma.

Authors:  Pei Zhang; Charles G Wu; Kathleen Mihalik; Maria Luisa Virata; Mei-Ying W Yu; Harvey J Alter; Stephen M Feinstone
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-09       Impact factor: 11.205

View more
  37 in total

1.  Immunogenetic and structural analysis of a class of HCV broadly neutralizing antibodies and their precursors.

Authors:  Fernando Aleman; Netanel Tzarum; Leopold Kong; Kenna Nagy; Jiang Zhu; Ian A Wilson; Mansun Law
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-28       Impact factor: 11.205

Review 2.  Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.

Authors:  Leopold Kong; Kelli N Jackson; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2015-04-29       Impact factor: 7.090

3.  Non-neutralizing epitopes induce robust hepatitis C virus (HCV)-specific antibody-dependent CD56+ natural killer cell responses in chronic HCV-infected patients.

Authors:  L Long; M Jia; X Fan; H Liang; J Wang; L Zhu; Z Xie; T Shen
Journal:  Clin Exp Immunol       Date:  2017-04-07       Impact factor: 4.330

4.  Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1.

Authors:  Leopold Kong; Erick Giang; Justin B Robbins; Robyn L Stanfield; Dennis R Burton; Ian A Wilson; Mansun Law
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-23       Impact factor: 11.205

5.  Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1.

Authors:  Ahmed Atef Mesalam; Isabelle Desombere; Ali Farhoudi; Freya Van Houtte; Lieven Verhoye; Jonathan Ball; Jean Dubuisson; Steven K H Foung; Arvind H Patel; Mats A A Persson; Geert Leroux-Roels; Philip Meuleman
Journal:  Virology       Date:  2017-11-10       Impact factor: 3.616

6.  Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein.

Authors:  Zhenyong Keck; Wenyan Wang; Yong Wang; Patrick Lau; Thomas H R Carlsen; Jannick Prentoe; Jinming Xia; Arvind H Patel; Jens Bukh; Steven K H Foung
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

7.  Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.

Authors:  Tinashe B Ruwona; Erick Giang; Travis Nieusma; Mansun Law
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

8.  Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.

Authors:  Zhen-yong Keck; Christine Girard-Blanc; Wenyan Wang; Patrick Lau; Adam Zuiani; Felix A Rey; Thomas Krey; Michael S Diamond; Steven K H Foung
Journal:  J Virol       Date:  2016-01-06       Impact factor: 5.103

Review 9.  Viral evasion and challenges of hepatitis C virus vaccine development.

Authors:  Brian G Pierce; Zhen-Yong Keck; Steven Kh Foung
Journal:  Curr Opin Virol       Date:  2016-09-19       Impact factor: 7.090

10.  Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses.

Authors:  William O Osburn; Anna E Snider; Brittany L Wells; Rachel Latanich; Justin R Bailey; David L Thomas; Andrea L Cox; Stuart C Ray
Journal:  Hepatology       Date:  2014-04-29       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.